Histamine pharmacology: four years on

The histamine field has moved on rapidly in the last four years, with expansion in roles and clinical development, particularly in the newest two of four histamine receptors. This themed volume is a testament to this expansion with 16 original and review articles spanning a wide spectrum of histamine‐related topics, with therapeutic translational relevance to addiction, dementias, anxiety disorders, cancers, vestibular disorders, migraine and autoimmune disorders.

[1]  E. Masini,et al.  Antagonism of histamine H4 receptors exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis , 2013, British journal of pharmacology.

[2]  M. Mehta,et al.  Potential enhancing effects of histamine H1 agonism/H3 antagonism on working memory assessed by performance and bold response in healthy volunteers , 2013, British journal of pharmacology.

[3]  R. Leurs,et al.  A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design , 2013, British journal of pharmacology.

[4]  H. Prast,et al.  Influence of the hippocampus on amino acid utilizing and cholinergic neurons within the nucleus accumbens is promoted by histamine via H1 receptors , 2013, British journal of pharmacology.

[5]  R. Leurs,et al.  A single‐point mutation (Ala280Val) in the third intracellular loop alters the signalling properties of the human histamine H3 receptor stably expressed in CHO‐K1 cells , 2013, British journal of pharmacology.

[6]  Jian-jun Wang,et al.  Postsynaptic mechanisms underlying the excitatory action of histamine on medial vestibular nucleus neurons in rats , 2013, British journal of pharmacology.

[7]  D. Finn,et al.  Twenty‐first century mast cell stabilizers , 2013, British journal of pharmacology.

[8]  P. Panula,et al.  Expression of histamine receptor genes Hrh3 and Hrh4 in rat brain endothelial cells , 2013, British journal of pharmacology.

[9]  P. Panula,et al.  Histamine is required for H3 receptor‐mediated alcohol reward inhibition, but not for alcohol consumption or stimulation , 2013, British journal of pharmacology.

[10]  B. Ellenbroek.  Histamine H3 receptors, the complex interaction with dopamine and its implications for addiction , 2013, British journal of pharmacology.

[11]  F. Sánchez-Jiménez,et al.  Pharmacological potential of biogenic amine–polyamine interactions beyond neurotransmission , 2013, British journal of pharmacology.

[12]  V. Medina,et al.  Therapeutic potential of histamine H4 receptor agonists in triple‐negative human breast cancer experimental model , 2013, British journal of pharmacology.

[13]  H. Stark,et al.  Profiling of histamine H4 receptor agonists in native human monocytes , 2013, British journal of pharmacology.

[14]  E. Haaksma,et al.  Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 983.36 of the human histamine H4 receptor , 2013, British journal of pharmacology.

[15]  R. Leurs,et al.  Detailed analysis of biased histamine H4 receptor signalling by JNJ 7777120 analogues , 2013, British journal of pharmacology.

[16]  M. Číž,et al.  Modulation of neutrophil oxidative burst via histamine receptors , 2013, British journal of pharmacology.

[17]  J. Dyhrfjeld-Johnsen,et al.  Histamine H4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability , 2012, British journal of pharmacology.